Several studies investigated complement activation markers in TTP patients with documented severe ADAMTS13 deficiency, showing lower serum levels of C3 and MAC during the acute phase (79, 80), correlating also with disease activity. Here, ADAMTS13 is linked to thrombotic thrombocytopenic purpura.